Juzentaihoto alleviates cisplatin‐induced renal injury in mice
Hiroki Yoshioka,Sarah Tominaga,Fumiya Amano,Sixun Wu,Shintaro Torimoto,Takeshi Moriishi,Yosuke Tsukiboshi,Satoshi Yokota,Nobuhiko Miura,Naoki Inagaki,Yuki Matsushita,Tohru Maeda
DOI: https://doi.org/10.1002/tkm2.1417
2024-07-10
Traditional & Kampo Medicine
Abstract:Aim Cisplatin is a highly effective anti‐cancer agent, but its clinical use is restricted due to severe renal toxicity. This study aimed to investigate the alleviative effects of juzentaihoto (JTT) in a mouse model of cisplatin‐induced renal injury. Methods Four groups of seven‐week‐old male C57BL/6J mice (control, JTT, cisplatin, and JTT + cisplatin groups) were used in the study. The JTT and JTT + cisplatin groups received oral JTT (500 mg/kg) once a day for three days. After 24 h, the cisplatin, and JTT + cisplatin groups were intraperitoneally injected with cisplatin (15 mg/kg). The mice in each group were euthanized 72 h after cisplatin administration, and blood and kidney samples were collected. Results Cisplatin injection decreased body weight and elevated plasma blood urea nitrogen and creatinine levels, while also increasing renal oxidative stress, inflammation, and cell death. These changes were alleviated by JTT administration. We also found that platinum accumulation in the kidneys following cisplatin injection was attenuated by JTT treatment. Furthermore, Mate1 expression levels (a cisplatin efflux transporter) were upregulated by JTT injection. Conclusion Our results demonstrated that JTT mitigated cisplatin‐induced renal injury in mice by alleviating oxidative stress, inflammation, and cell death, achieved through the upregulation of the cisplatin efflux transporter Mate1.
English Else